Sector News

Pfizer rejigs executive roster to put Albert Bourla at Read's right hand

November 13, 2017
Life sciences

Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read. It’s Albert Bourla, who’s headed up the company’s Innovative Health unit since early 2016.

Adding a COO to the executive roster will allow Read to “spend more time focusing on the company’s long-term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry,” the CEO said in the statement.

It also sets up Bourla at Read’s right hand, a spot that’s auspicious for his future at the company, as the Wall Street Journal noted. Read is 64, and though he’s not ready to make an exit, he did want to set up a plan for his succession when the time comes, the newspaper reported, citing an anonymous source.

Bourla will move into the newly created slot on Jan. 1, the company said in a Monday statement. He’ll oversee R&D, sales and strategy across the company, Pfizer said. His promotion will trigger other management switches; John Young, who’s been running Pfizer’s Established Products unit, will move into Bourla’s current job, and Angela Hwang, who heads up the company’s inflammation and immunology business, will take over at Established Products.

In announcing the move, Pfizer emphasized Bourla’s recent success at driving growth in the Innovative Health business, with 9% revenue growth so far this year. Cancer med Ibrance, which Bourla handled in his previous role as president of vaccines, oncology and consumer health, has been among the company’s most successful recent launches.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach